1. Aday L.A. et al. (1993) Evaluating the Medical Care System:
Effectiveness, Efficiency, and Equity. Health Administration Press,
University of Michigan (Ann Arbor, MI).
2. Ades A.E., Claxton K. and Sculpher M. (2006) Evidence Synthesis,
Parameter Correlation and Probabilistic Sensitivity Analysis. Health
Economics 15(4): 373-381.
3. Ades A.E. and Cliffe S. (2002) Markov chain Monte Carlo estimation of
a multiparameter decision model: consistency of evidence and the
accurate assessment of uncertainty. Medical Decision Making 22: 359–
371.
4. Anderson J.P. et al. (1986) Policy space areas and properties of benefit-cost/utility analysis. JAMA 255: 794-795.
5. Arrow K.J. (1963) Uncertainty and the Welfare Economics of Medical
Care. American Economic Review 53(3): 941–973.
6. Black W.C. (1990) The CE Plane: A Graphic Representation of Cost-Effectiveness. Medical Decision Making 10: 212-214.
7. Boadway R. and Bruce N. (1984) Welfare Economics. Oxford: Basil
Blackwell.
8. Briggs A. and Fenn P. (1998) Confidence Intervals or Surfaces?
Uncertainty on the Cost-Effectiveness Plane. Health Economics 7: 723-740.
Sağlık Sektöründe Bir Verimlilik Değerlendirme Tekniği Olarak Maliyet-Etkililik 133
9. Brook R. and Lohr K. (1985) Efficacy, Effectiveness, Variations, and
Quality: Boundary-Crossing Research. Medical care 23(suppl.): 710-722.
10. Claxton K., Sculpher M., McCabe C. et al. (2005) Probabilistic
Sensitivity Analysis for NICE Technology Assessment: Not An Optional
Extra. Health Economics 14: 339–347.
11. Coast J. (2004) Is economic evaluation in touch with society's health
values? British Medical Journal 329: 1233-1236.
12. Cookson R. et al. (2001) Worng SIGN, NICE Mess: Is National
Guidance Distorting Allocation of Resources? British Medical Journal
323: 743-745.
13. Diel R., Nienhaus A. and Loddenkempe R. (2007) Cost-effectiveness of
Interferon-Release Assay Screening for Latent Tuberculosis Infection
Treatment in Germany. CHEST 131:1424–1434.
14. Doubilet P., Begg C.B., Weinstein M.C., Braun P. and McNeil B.J.
(1985) Probabilistic sensitivity analysis using Monte Carlo simulation. A
practical approach. Medical Decision Making 5(2): 157-177
15. Drummond M.F. et al. (2006) Methods for the Economic Evaluation of
Health Care Programmes. Oxford University Press Inc., New York.
16. Drummond M.F. (2003) The Use of Economic Information by
Reimbursement Authorities. Rheumatology 42(Supply. 3): iii60-iii63.
17. Drummond M.F., Aguiar-Ibáñez, R. and Nixon, J. (2006) Economic
Evaluation. Singapore Medical Journal 47(6): 456-462.
18. Ebri A., Kuper H. and Wedner S. (2007) Cost-Effectiveness of
Cycloplegic Agents: Results of a Randomized Controlled Trial in
Nigerian Children. Investigative Ophthalmology & Visual Science
48(3): 1025-1031.
134 Hacettepe Sağlık İdaresi Dergisi, Cilt:10, Sayı:2 (2007)
19. Elliott R. and Payne K. (2005) Essentials of Economic Evaluation in
Health Care. Pharmaceutical Press, London.
20. Folland S. et al. (1997) The Economics of Health and Health Care.
New Jersey: Prentice Hall.
21. Gafni A. and Birch S. (2006) Incremental Cost-effectiveness ratios
(ICERs): The Silence of the Lambda. Social Science and Medicine 62:
2091-2100.
22. Gage H. et al. (2006) Evaluating rehabilitation using cost-consequences
analysis: an example in Parkinson's disease. Clinical Rehabilitation 20:
232-238.
23. Groot KB. et al. (2007). Limitations of acceptability curves for
presenting uncertainty in cost-effectiveness analysis. Medical Decision
Making 27: 101-111.
24. Hutubessy R. et al. (2003) Generalized Cost-Effectiveness Analysis for
National-level Priority-setting in the Health Sector. Cost Effectiveness
and Resource Allocation 1: 8-20.
25. Jacobs R. et al. (2006) Measuring Efficiency in Health Care. Cambridge
University Press, UK.
26. James M. et al. (2005) A Cost Consequences Analysis of Local
Corticosteroid Injection and Physiotherapy for the Treatment of New
Episodes of Unilateral Shoulder Pain in Primary Care. Rheumatology
44(11):1447-1451.
27. Lipscomb J., Weinstein M.C. and Torrance G.W. (1996) “Time
Preference”. In Gold M.R., Siegel J.E., Russell L.B. and Weinstein M.C.
(eds.) Cost Effectiveness in Health and Medicine, pp:214-246. Oxford
University Press.
28. Liu et al. (2005) Health Care and Pharmaceutical Spending in
Turkey. SUVAK, Ankara. (www.suvak.org.tr)
Sağlık Sektöründe Bir Verimlilik Değerlendirme Tekniği Olarak Maliyet-Etkililik 135
29. Lord J. and Asante M.A. (1999) Estimating Uncertainty Ranges for Costs
by the Bootstrap Procedure Combined with Probabilistic Sensitivity
Analysis. Health Economics 8: 323–333.
30. Mandelblatt J.S. et al. (1996) “Assessing the Effectiveness of Health
Interventions”. In Gold M.R., Siegel J.E., Russell L.B. and Weinstein
M.C. (eds.) Cost Effectiveness in Health and Medicine, pp:135-175.
Oxford University Press.
31. Manning W.G., Fryback D.G. and Weinstein M.C. (1996) “Time
Preference”. In Gold M.R., Siegel J.E., Russell L.B. and Weinstein M.C.
(eds.) Cost Effectiveness in Health and Medicine, pp:214-246. Oxford
University Press.
32. Meltzer M.I. (2001) Introduction to Health Economics for Physicians.
Lancet 358: 993–998.
33. Multicentre Aneurysm Screening Study (MASS) (2002) Cost
effectiveness analysis of screening for abdominal aortic aneurysms based
on four year results from randomised controlled trial. British Medical
Journal 325:1135.
34. Murray C.J.L. et al. (2000) Development of WHO Guidelines on
Generalized Cost-effectiveness Analysis. Health Economics 9: 235-251.
35. Mushkin S.J. (1958) Toward A Definition of Health Economics. Public
Health Reports 73(9): 785- 793.
36. Mushkin S.J. (1962) Health as an Investment. Journal of Political
Economy 70(5): 129-157.
37. Plant P.K., Owen J.L., Parrott S. and Elliott M.W. (2003) Cost
Effectiveness of Ward Based Non-Invasive Ventilation for Acute
Exacerbations of Chronic Obstructive Pulmonary Disease: Economic
Analysis of Randomised Controlled Trial. British Medical Journal 326:
956.
136 Hacettepe Sağlık İdaresi Dergisi, Cilt:10, Sayı:2 (2007)
38. Robertson J. et al. (2003) Use of Pharmacoeconomics in Prescribing
Research. Part 1: Costs – Moving Beyond the Acquisition Price for
Drugs. Journal of Clinical Pharmacy and Therapeutics 28: 73–79.
39. Samuelson P.A. and Nordhaus W.D. (1995) Micro Economics. McGraw-Hill, Inc.
40. Sendi P.P. and Briggs A.H. (2001) Affordability and Cost-Effectiveness:
Decision-making on the Cost-Effectiveness Plane. Health Economics
10: 675-680.
41. Sendi P., Gafni A. and Birch S. (2002) Opportunity Costs and
Uncertainty in the Economic Evaluation of Health Care Interventions.
Health Economics 11: 23-31.
42. Stinnett A. A. and Mullahy J. (1998) Net Health Benefits: A New
Framework for the Analysis of Uncertainty in Cost-Effectiveness
Analysis. Medical Decision Making 18(2 Suppl): S68-80.
43. Suraratdecha C., Ramana C.B.S.V., Kaipilyawar S., Krishnamurthy
J.V.G., Sivalenka S., Ambatipudi N., Gandhi S., Umashankar K. &
Cheyne J. (2008) Cost and effectiveness analysis of immunization
service delivery support in Andhra Pradesh, India. Bulletin of the World
Health Organization 86. Elektronik Sürüm
(http://www.ncbi.nlm.nih.gov) (Erişim Tarihi 13 Haziran 2008)
44. Tan-Torres Edejer T. et al. (2003) Making Choices in Health Care: WHO
Guide to Cost-Effectiveness Analysis. World Health Organization,
Geneva.
45. Tatar M. (2007) Pharmaprofile. Turkey. Pharmaceutical Pricing and
Reimbursement Information (PPRI) (www.ppri.oebig.at).
46. Van Hout B. et al. (1994) Costs, Effects and C/E Ratios Alongside A
Clinical Trial. Health Economics 3: 309-319.
Sağlık Sektöründe Bir Verimlilik Değerlendirme Tekniği Olarak Maliyet-Etkililik 137
47. Wake N. et al. (2000) Cost-Effectiveness of Intensive Insulin Therapy for
Type 2 Diabetes: A 10-Year Follow-up of the Kumamoto Study.
Diabetes Research and Clinical Practice 48(3): 201-210.
48. Walley T. (2004) Pharmacoeconomics and Economic Evaluation of Drug
Therapies. In du Souich P. et al. (eds.) The IUPHAR Compendium of
Basic Principles for Pharmacological Research in Humans, pp:67-75.
Department of Pharmacology College of Medicine, University of
California, USA.
49. WHO (2007) An Overview of the Rationale, Activities and Goals of
WHO-CHOICE, http://www.who.int/choice/description/importance/en,
27.08.2007
Thank you for copying data from http://www.arastirmax.com
